Financials data is unavailable for this security.
View more
Year on year Perrigo Company PLC grew revenues 4.58% from 4.45bn to 4.66bn while net income improved from a loss of 140.60m to a smaller loss of 12.70m.
| Gross margin | 36.07% |
|---|---|
| Net profit margin | -3.34% |
| Operating margin | -0.43% |
| Return on assets | -1.34% |
|---|---|
| Return on equity | -3.16% |
| Return on investment | -1.51% |
More ▼
Cash flow in USDView more
In 2023, Perrigo Company PLC increased its cash reserves by 25.07%, or 150.60m. The company earned 405.50m from its operations for a Cash Flow Margin of 8.71%. In addition the company used 77.50m on investing activities and also paid 187.20m in financing cash flows.
| Cash flow per share | 1.35 |
|---|---|
| Price/Cash flow per share | 19.48 |
| Book value per share | 33.45 |
|---|---|
| Tangible book value per share | -11.11 |
More ▼
Balance sheet in USDView more
| Current ratio | 2.56 |
|---|---|
| Quick ratio | 1.77 |
| Total debt/total equity | 1.04 |
|---|---|
| Total debt/total capital | 0.51 |
More ▼
Growth rates in USD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 5.00% and 96.66%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally, five year annualized dividend per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.39% |
|---|---|
| Div growth rate (5 year) | 7.52% |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -1,525.94 |
More ▼
